(R)-Crizotinib is a dual inhibitor of c-Met and anaplastic lymphoma kinase (ALK) with IC50 values of 8 nM and 20 nM, respectively, in a cell-based assay. It selectively inhibits c-Met and ALK over several other tyrosine kinases, including Ron, Tie2, Abl, LCK, and VEGFR2. (R)-Crizotinib effectively suppresses the proliferation of cancer cell lines with MET amplifications and induces apoptosis in MET-amplified lung cancer cells. It also acts as a ROS1 inhibitor. Reagent grade, for research use only.
Usually ships within 24 hours.